Authors: CHINJE EC SAUNDERS MP FRANKLIN G ROBERTSON N PATTERSON AV STRATFORD IJ

Citation: Ec. Chinje et al., USING GENE-THERAPY TO DETERMINE THE MECHANISM OF HYPOXIC ACTIVATION OF TIRAPAZAMINE, British Journal of Cancer, 78, 1998, pp. 27-27

Authors: ULHAQ S NAYLOR MA CHINJE EC THREADGILL MD STRATFORD IJ

Citation: S. Ulhaq et al., S-2-AMINO-5-(2-NITROIMIDAZOL-1-YL)PENTANOIC ACID - A MODEL FOR POTENTIAL BIOREDUCTIVELY ACTIVATED PRODRUGS FOR INHIBITORS OF NITRIC-OXIDE SYNTHASE (NOS) ACTIVITY, Anti-cancer drug design, 12(1), 1997, pp. 61-65

Authors: PATTERSON AV SAUNDERS MP CHINJE EC TALBOT DC HARRIS AL STRATFORD IJ

Citation: Av. Patterson et al., OVEREXPRESSION OF HUMAN NADPH-CYTOCHROME-C (P450) REDUCTASE CONFERS ENHANCED SENSITIVITY TO BOTH TIRAPAZAMINE (SR 4233) AND RSU 1069, British Journal of Cancer, 76(10), 1997, pp. 1338-1347

Authors: BARHAM HM INGLIS R CHINJE EC STRATFORD IJ

Citation: Hm. Barham et al., DEVELOPMENT AND VALIDATION OF A SPECTROPHOTOMETRIC ASSAY FOR MEASURING THE ACTIVITY OF NADH - CYTOCHROME B(5) REDUCTASE IN HUMAN TUMOR-CELLS, British Journal of Cancer, 74(8), 1996, pp. 1188-1193

Authors: PATTERSON AV BARHAM HM CHINJE EC ADAMS GE HARRIS AL STRATFORD IJ

Citation: Av. Patterson et al., IMPORTANCE OF P450 REDUCTASE-ACTIVITY IN DETERMINING SENSITIVITY OF BREAST-TUMOR CELLS TO THE BIOREDUCTIVE DRUG, TIRAPAZAMINE (SR-4233), British Journal of Cancer, 72(5), 1995, pp. 1144-1150